Efficacy and Safety of Carboplatin/Nanoparticle Albumin-Bound Paclitaxel Combination Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer or Recurrent Non-Small-Cell Lung Cancer Following Surgery

A retrospective analysis on carboplatin (CBDCA)/nanoparticle albumin-bound paclitaxel(nab-PTX) combination chemotherapy was conducted in patients with non-small-cell lung cancer (NSCLC)to evaluate both the efficacy and toxicity based on age, treatment line, histology, and underlying diseases. A total of 27 patients with advanced or recurrent NSCLC following surgery who received CBDCA /nab-PTX as first- and second -line combination chemotherapy, respectively, were investigated from March 2013 to December 2015. The overall response rate, median progression free survival, and median overall survival of all patients were 37.0%, 5.5 months, and 11.4 months, respectively. With regard to toxicity, 3.7%and 14.8%of all patients had peripheral disorder and interstitial lung disease (ILD), respectively. Treatment related deaths were not observed. No difference in the efficacy based on age, treatment line, histology, and underlying diseases was observed. CBDCA/nab-PTX combination chemotherapy was safe for elderly patients and those with ILD. However, the occurrence of new interstitial lung lesions should be carefully considered.

Authors: Shimabukuro I, Noguchi S, Uyama K, Torii R, Ishimoto H, Yoshii C, Tanaka F, Yatera K, Mukae H. ; Full Source: Gan To Kagaku Ryoho. 2018 Sep;45(9):1305-1310.